Arima Genomics reported early clinical results for its Aventa Hi‑C lymphoma sequencing assay that identified clinically significant gene fusions and rearrangements in FFPE lymphoma samples where FISH was inconclusive. The proximity‑ligation Hi‑C approach preserves three‑dimensional genome interactions and amplified signals, enabling detection of rearrangements and breakpoints that standard panels can miss. Arima, which recently expanded its clinical lab footprint after a Series C, argues Hi‑C assays could replace hypothesis‑driven FISH panels and streamline workflows in pathology labs. If validated in larger cohorts, Hi‑C diagnostics would alter cytogenetics practice by enabling comprehensive structural variant profiling from routine FFPE specimens.